Advances, Challenges, and the Landscape of PARPi Therapy—A Narrative Review

George Dimitrov,Radoslav Mangaldzhiev,Chavdar Slavov,Elenko Popov
DOI: https://doi.org/10.3390/ijms25042184
IF: 5.6
2024-02-12
International Journal of Molecular Sciences
Abstract:After recent approvals, poly-adenosine diphosphate [ADP]-ribose polymerase inhibitors (PARPis) have emerged as a frontline treatment for metastatic castration-resistant prostate cancer (mCRPC). Unlike their restricted use in breast or ovarian cancers, where approval is limited to those with BRCA1/2 alterations, PARPis in mCRPC are applied across a broader spectrum of genetic aberrations. Key findings from the phase III PROPEL trial suggest that PARPis' accessibility may broaden, even without mandatory testing. An increasing body of evidence underscores the importance of distinct alterations in homologous recombination repair (HRR) genes, revealing unique sensitivities to PARPis. Nonetheless, despite the initial effectiveness of PARPis in treating BRCA-mutated tumors, resistance to therapy is frequently encountered. This review aims to discuss patient stratification based on biomarkers and genetic signatures, offering insights into the nuances of first-line PARPis' efficacy in the intricate landscape of mCRPC.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
This paper aims to explore the progress, challenges of precision medicine in metastatic castration - resistant prostate cancer (mCRPC) and the prospects of poly - ADP - ribose polymerase inhibitor (PARPi) treatment. Specifically, the paper attempts to address the following core issues: 1. **Application of PARPi in mCRPC**: - The paper discusses the application of PARPi as a first - line treatment drug in mCRPC, especially in patients with homologous recombination repair (HRR) gene mutations. Unlike in breast or ovarian cancer where it is limited to patients with BRCA1/2 mutations, the application range of PARPi in mCRPC is broader, covering multiple genetic abnormalities. 2. **Efficacy and resistance of PARPi treatment**: - Although PARPi has shown initial effectiveness in treating BRCA - mutated tumors, resistance is a common problem. The paper explores in detail the mechanisms of PARPi resistance, especially through the restoration of HRR function, such as BRCA1/2 repair or changes in the DNA damage response pathway. 3. **Patient stratification and biomarkers**: - The paper emphasizes the importance of patient stratification based on biomarkers and genetic characteristics to optimize the treatment effect of PARPi and reduce toxicity. The study found that different HRR gene mutations have different sensitivities to PARPi, so more precise stratification strategies are required. 4. **Results of clinical trials**: - The paper summarizes the results of several key clinical trials (such as PROpel, TALAPRO - 2, CASPAR and MAGNITUDE), which evaluated the effect of the combination of PARPi and androgen receptor signaling inhibitors (ARSis). The results show that this combination therapy is particularly effective in HRR - mutated patients, but has limited effect in non - HRR - mutated patients. 5. **Future directions**: - The paper proposes future research directions, including further exploration of the combination of PARPi with other drugs (such as platinum - based drugs, immune checkpoint inhibitors, etc.), and the development of more comprehensive genetic testing methods to better guide treatment decisions. In conclusion, this paper is committed to providing a scientific basis for precision medicine in mCRPC by reviewing existing research and clinical data, and proposing directions for future research and clinical practice.